Retroviral gene transfer to human epidermal keratinocytes correlates with integrin expression and is significantly enhanced on fibronectin.
Human epidermal keratinocytes are an important target for gene therapy because they can be easily expanded in culture and used to generate skin substitutes for the treatment of wounds, genetic diseases of the skin, and for delivery of proteins to the systemic circulation. Although retroviral transduction results in permanent genetic modification, differentiation and loss of transduced cells from the epidermis results in temporary transgene expression. To ensure permanent genetic modification, epidermal stem cells must be transduced with high efficiency. We evaluated gene transfer on two different substrates and found that the efficiency of gene transfer is substantially higher on a substrate of recombinant fibronectin (FN), when compared to tissue culture plastic (TCP). The rate of retroviral transduction on FN is four times faster than transduction on tissue culture plates and is independent of polybrene (PB). The transduction efficiency correlates with the levels of expression of integrin subunits alpha5, alpha2, and beta1, which have been shown to correlate with stem cell phenotype. Notably, cells that adhere rapidly to FN are transduced more efficiently than slowly adherent cells. In addition, integrin-blocking antibodies decrease the efficiency of gene transfer in a dose-dependent manner. Our results suggest that FN may enhance retroviral gene transfer to the least differentiated cells, thereby increasing the potential of genetically modified keratinocytes to treat short- and long-term disease states.
Bajaj
Bharat
B
Bioengineering Laboratory, Department of Chemical Engineering, University at Buffalo, State University of New York, Amherst, NY 14260, USA.
Behshad
Shahram
S
Andreadis
Stelios T
ST
D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology; D002448:Cell Adhesion; D018929:Cell Culture Techniques / Q000295:instrumentation; D002478:Cells, Cultured / Q000378:metabolism / Q000821:virology; D003470:Culture Media / Q000494:pharmacology*; D005353:Fibronectins / Q000494:pharmacology*; D005822:Genetic Vectors / Q000235:genetics / Q000502:physiology*; D006583:Hexadimethrine Bromide / Q000494:pharmacology; D006801:Humans; D039421:Integrin alpha2 / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D039482:Integrin alpha5 / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D019012:Integrin beta1 / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D015603:Keratinocytes / Q000378:metabolism / Q000821:virology*; D010969:Plastics; D011994:Recombinant Proteins / Q000494:pharmacology; D012190:Retroviridae / Q000235:genetics / Q000502:physiology*; D014161:Transduction, Genetic
D000911:Antibodies, Monoclonal; D003470:Culture Media; D005353:Fibronectins; D039421:Integrin alpha2; D039482:Integrin alpha5; D019012:Integrin beta1; D010969:Plastics; D011994:Recombinant Proteins; D006583:Hexadimethrine Bromide